Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents With Acute Bipolar Mania Publisher Pubmed



Mousavi SY1 ; Khezri R1 ; Karkhanehyousefi MA1 ; Mohammadinejad P1 ; Gholamian F1 ; Mohammadi MR1 ; Zeinoddini A1 ; Akhondzadeh S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran

Source: Journal of Child and Adolescent Psychopharmacology Published:2017


Abstract

Objective: Recent studies have focused on the role of inflammatory cascades as one of the possible etiologic factors of bipolar disorder. We hypothesize that celecoxib, through its anti-inflammatory properties, may have a therapeutic role in acute bipolar mania. Patients and Methods: Forty-two adolescent inpatients with the diagnosis of acute bipolar mania participated in a parallel, randomized, double-blind controlled trial, and 40 patients underwent an 8-week treatment with either celecoxib (100 mg twice daily) or placebo as an adjunctive treatment to lithium and risperidone. Patients were evaluated using Young Mania Rating Scale (YMRS) at baseline and weeks 2, 4, and 8. The primary outcome measure was to assess the efficacy of celecoxib compared with placebo in improving mania symptoms. Result: General linear model repeated measures showed significant effect for time × treatment interaction on YMRS scores [F (2.54, 96.56) = 3.21, p = 0.03]. Significantly greater improvement was observed in YMRS scores in the celecoxib group compared with the placebo group from baseline YMRS score at week 8 (p = 0.04). Although a 35% greater response to treatment (considering a Clinical Global Impressions-Improvement score of ≤2, very much/much improved) was observed in the celecoxib group compared with the placebo group, the difference did not reach the statistical significance level (p = 0.09). No serious adverse event was reported. Conclusions: Celecoxib may be an effective adjuvant therapy in treatment of manic episodes (without psychotic features) of adolescents with bipolar mood disorder. The mood-stabilizing role of this drug might be mediated through its action on inflammatory cascades. Copyright © 2017, Mary Ann Liebert, Inc.
Experts (# of related papers)
Other Related Docs
14. Monoclonal Antibody a Promising Treatment for Depression, Avicenna Journal of Medical Biotechnology (2019)
29. Tlr/Mtor Inflammatory Signaling Pathway: Novel Insight for the Treatment of Schizophrenia, Canadian Journal of Physiology and Pharmacology (2023)
30. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)